Eli

Eli Lilly and Company has entered a worldwide licensing collaboration with France-based Adocia to develop an ultra-rapid insulin, BioChaperone Lispro, to treat people with type 1 and type 2 diabetes.

BioChaperone Lispro will be based on Adocia’s proprietary BioChaperone technology, and is currently in Phase Ib trials. It is being developed to optimise glucose levels during and after meals.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, Lilly will take responsibility for future development, manufacturing and commercialisation of BioChaperone Lispro, which will involve total up-front and milestone payments of $570m.

Lilly Diabetes president Enrique Conterno said: "An ultra-rapid acting insulin, if approved by regulators, could provide a new important treatment option for people with type 1 and type 2 diabetes."

"The company said the benefits of BioChaperone Lispro include greater flexibility in the timing of insulin injections, lower variability of post-meal blood glucose elevations, lower rates of hypoglycemia and better overall glucose control."

With potential future payments of up to $280m, Adocia will secure a total upfront fee of $50m. It is also provided with an option to receive sales milestones of up to $240m, if the product reaches certain development and regulatory milestones.

See Also:

Lilly will reimburse Adocia for certain research and development expenses and the BioChaperone Lispro concentrated formulation is also part of the deal, according to Lilly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said the benefits of BioChaperone Lispro include greater flexibility in the timing of insulin injections, lower variability of post-meal blood glucose elevations, lower rates of hypoglycemia and better overall glucose control.

Adocia president Gerard Soula said: "It is a great day for Adocia and Lilly, a global leader in diabetes treatment, to initiate a new collaboration for the development of an innovative ultra-rapid formulation of insulin lispro."

Lilly said that Adocia retains the right to develop and license its insulin programmes unrelated to prandial ultra-rapid insulin.

Image: Eli Lilly headquarters. Photo: courtesy of Guanaco152003.